Drug Profile
Research programme: liposomal therapeutics - Plus Therapeutics
Alternative Names: ATI-0721; ATI-1150; ATI-1186; ATI-1230; CRM 2100Latest Information Update: 10 Sep 2019
Price :
$50
*
At a glance
- Originator Azaya Therapeutics
- Developer Plus Therapeutics
- Class Antineoplastics; Skin disorder therapies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Scleroderma